Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
NCT03065387 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2026-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participation” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FKBP1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), Mirdametinib + Sirolimus (NCT06876142)
- 2026-11-10Phase 3 first posted: Polisorb Joint Stock Company, Colloidal Silicon Dioxide + Basic Therapy for Atopic Dermatitis (NCT07929181)
- 2026-11-05Results posted on the registry: M.D. Anderson Cancer Center, Bevacizumab + Cetuximab (NCT01552434)
- 2026-11-05Also stopped (terminated): M.D. Anderson Cancer Center, Bevacizumab + Cetuximab (NCT01552434)
- 2026-10-29Phase 3 first posted: Cairo University, Crisaborole 2% topical ointment + tacrolimus 0.1% (NCT07904910)
- 2026-10-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Donor-derived Mesenchymal Stromal Cells + alemtuzumab (NCT03504241)
- 2026-10-29Results posted on the registry: Northwestern University, Erythropoietin (NCT05325073)
- 2026-10-23Phase 3 first posted: Cairo University, Crisaborole 2% topical ointment + tacrolimus ointment 0.1% (NCT07892339)
- 2026-10-22Results posted on the registry: Rapamycin Holdings Inc., Encapsulated Rapamycin (eRapa) (NCT04230499)
- 2026-10-22Also stopped (terminated): Odense University Hospital, Short duration of aspirin and prasugrel + Conventional duration of aspirin and prasugrel (NCT06718179)
- 2026-10-20Results posted on the registry: M.A. Med Alliance S.A., a drug against FKBP1A (NCT04280029)
- 2026-10-15Also stopped (suspended): City of Hope Medical Center, Fludarabine + Melphalan (NCT06195891)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-15Also stopped (withdrawn): Brigham and Women's Hospital, a drug against FKBP1A (NCT02741102)
- 2026-10-06Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Sirolimus (NCT02979873)
- 2026-10-06Results posted on the registry: Vascular Therapies, Inc., Sirolimus (NCT05425056)
- 2026-10-01Phase 3 first posted: Amgen, Inebilizumab + Tacrolimus (NCT07851220)
- 2026-09-30Results posted on the registry: Indiana University, Tacrolimus single dose + Epidiolex single dose (NCT05490511)
- 2026-09-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), tocilizumab + Placebo (NCT03644667)
- 2026-09-28Results posted on the registry: Aadi Bioscience, Inc., nab-sirolimus (NCT05103358)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Belatacept + methylprednisolone (NCT01790594)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Tacrolimus (CNI) Withdrawal + Standard Immunosuppressive Therapy (NCT01517984)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Alemtuzumab + MMF (NCT01436305)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Anti-thymocyte Globulin (Rabbit) + belatacept (NCT01856257)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper) + Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper) (NCT01278745)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision